Virtual Reality-Based Branching Scenario Education: Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a virtual reality (VR) headset. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.
Tablet-Based Branching Scenario Education: Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a tablet. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.
Study summary
This randomized controlled trial aims to evaluate the effects of nurse-led branching scenario-based education delivered through virtual reality and tablet on cardiovascular disease risk awareness and adherence to antiplatelet medication in patients with coronary artery disease. Participants will be randomly assigned to a virtual reality education group, a tablet-based education group, or a control group receiving routine hospital education. Cardiovascular disease risk awareness and medication adherence will be assessed before and after the educational intervention and during follow-up.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Aged 18-65 years.
* Diagnosed with coronary artery disease.
* Newly initiated on antiplatelet therapy.
* Conscious and able to communicate.
* Physically and cognitively able to use a virtual reality headset.
* Able to read, write, and understand Turkish.
* Willing to provide written informed consent.
* Willing to participate in the education and follow-up process.
* Has not previously received education about coronary artery disease.
* Able to use a smartphone.
Exclusion Criteria:
* Cognitive impairment or mental illness preventing communication.
* Visual or hearing impairment preventing participation in the virtual reality education.
* Participation in another clinical study at the same time.
* Diagnosis of malignant disease.
* Bleeding disorder or active bleeding risk.
* Hospitalization within the previous 3 months due to acute myocardial infarction, stroke, or another serious cardiovascular event.
* Unable to understand the educational materials.
* Refusal to provide written informed consent.
Primary outcome measure(s)
cardiovascular disease risk awareness assessment scale score — baseline and immediately after the educational intervention Change in cardiovascular disease risk awareness, assessed using the Turkish validated 22-item Cardiovascular Disease Risk Awareness Assessment Scale (CVD-RAAS). The knowledge domain score ranges from 0 to 8, with higher scores indicating higher knowledge about myocardial infarction and stroke. The total score for the 14-item Likert-type awareness subscales ranges from 14 to 56, with higher scores indicating greater awareness of cardiovascular disease risks, healthier dietary intentions, and higher readiness for behavioral change.
medication adherence report scale score — Baseline, immediately after the intervention, and 3 months follow-up Change in medication adherence, assessed using the Turkish validated 5-item Medication Adherence Report Scale (MARS-5). Each item is scored on a 5-point Likert scale (1 = always to 5 = never). Total scores range from 5 to 25, with higher scores indicating greater medication adherence.
Cardiovascular Disease Risk Awareness Assessed by the Cardiovascular Disease Risk Awareness Assessment Questionnaire — Baseline, immediately after the intervention, and 3 months after the intervention. Cardiovascular disease risk awareness will be assessed using the Turkish version of the Cardiovascular Disease Risk Awareness Assessment Questionnaire (CDRAAQ), a 22-item instrument consisting of an 8-item knowledge section and three subscales: perceived risk of heart attack/stroke, healthy eating intentions, and perceived benefits and intentions to change. The knowledge items are scored as correct or incorrect, with each correct response receiving 1 point. The subscale items are rated on a 4-point Likert scale from 1 (strongly disagree) to 4 (strongly agree), with reverse scoring applied where appropriate. Higher scores indicate greater cardiovascular disease risk awareness, greater knowledge of heart attack and stroke, and greater readiness for health-related behavioral change.
Trial sites (1)
Facility
City
Region
Status
Bolu Abant İzzet Baysal University
Bolu
Turkey (Türkiye)
More Abant Izzet Baysal University trials in Turkey
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.